U.S., Nov. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07943078) titled 'A Study of JNJ-99220732 in Participants With Advanced or Metastatic Solid Tumors' on Nov. 12.

Brief Summary: The purpose of this study is to find out how safe and well-tolerated JNJ-99220732 is and to find out the most suitable dose ([putative] recommended phase 2 dose [pRP2D] regimen[s]) of JNJ-99220732 (Part 1-Dose Escalation). Also, to find out how safe and well-tolerated JNJ-99220732 is at the pRP2D regimen(s) as determined in Part 1 (Part 2- Dose Expansion).

Study Start Date: Dec. 01

Study Type: INTERVENTIONAL

Condition: Neoplasms

Intervention: DRUG: JNJ-99220732

JNJ-99220732 will be administered intravenously.

Recruitm...